The Study
Semaglutide reduces the absolute risk of major cardiovascular events by 1.5%
This study shows that people who took semaglutide seemed to have fewer heart problems than those who didn't, but we can't be sure it was the medicine that caused the difference because we don't know for sure how the study was run. It's like seeing two groups do different things and noticing a pattern, but not being sure one caused the other.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
This study looked at whether a drug called semaglutide helps prevent heart problems in people with heart disease but no diabetes. It found the drug slightly lowers the chance of some heart issues but causes stomach problems in many people.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 559 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1The heart benefit is small for an individual, but meaningful at a population level.
- 2However, the high rate of side effects means many won't tolerate the drug.
- 3Over 34 months, 1.5% fewer people on semaglutide had major heart events.
- 4One in 67 people needed to take it to prevent one event.
- 5But 1 in 12 stopped taking it due to stomach side effects.
- 6Heart attacks dropped from 3.7% to 2.7%.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Related Content
Claims (4)
If you're obese and have heart disease but not diabetes, taking semaglutide might lower your chances of having a serious heart problem by 20%.
If you're 45 or older, have heart disease, and are overweight but don’t have diabetes, taking semaglutide for about 3 years might lower your chance of having a serious heart problem by a small amount — about 1.5%. That means 67 people need to take it for one person to avoid a heart event, which gives a clearer picture than the often-shared 20% drop in risk.
For people with heart disease but not diabetes, taking semaglutide seems to lower the chance of having a non-fatal heart attack over about three years — 2.7% of users had one versus 3.7% who didn’t take it.
For people with heart disease, taking semaglutide means about 1 in 12 will stop treatment because of stomach problems like nausea or diarrhea — much more common than with a dummy pill.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.